Evidence before this study
The
primary progression-free survival analysis of the ICON7 trial reported
significantly improved progression-free survival when bevacizumab was
added to standard chemotherapy in newly diagnosed ovarian cancer. The
effect was greatest in patients at high risk of disease progression.
Similar progression-free survival findings were reported in the GOG-218
trial.
Added value of this study
In
a planned mature analysis of overall survival, no difference in overall
survival was noted between those patients who received bevacizumab plus
chemotherapy and those who received chemotherapy alone. However, in
subgroup analyses, improved overall survival was noted in patients at
high risk of disease progression who received bevacizumab compared with
those who did not.
Implications of all the available evidence
Bevacizumab
may have a role in the treatment of patients with poor-prognosis
ovarian cancer. Future work should address questions of treatment
duration, targeting, timing, re-challenge, and dose fractionation.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.